nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—Lupus-like syndrome—Dapsone—leprosy	0.164	0.169	CcSEcCtD
Methyldopa—Pericarditis—Thalidomide—leprosy	0.0458	0.0471	CcSEcCtD
Methyldopa—Parkinsonism—Thalidomide—leprosy	0.0436	0.0449	CcSEcCtD
Methyldopa—Foetor hepaticus—Thalidomide—leprosy	0.0349	0.0359	CcSEcCtD
Methyldopa—Liver disorder—Thalidomide—leprosy	0.029	0.0299	CcSEcCtD
Methyldopa—Psychotic disorder—Dapsone—leprosy	0.0274	0.0282	CcSEcCtD
Methyldopa—Endocrine disorder—Thalidomide—leprosy	0.0239	0.0246	CcSEcCtD
Methyldopa—Pancreatitis—Dapsone—leprosy	0.0238	0.0245	CcSEcCtD
Methyldopa—Amenorrhoea—Thalidomide—leprosy	0.0225	0.0232	CcSEcCtD
Methyldopa—Hepatocellular injury—Thalidomide—leprosy	0.0198	0.0204	CcSEcCtD
Methyldopa—Colitis—Thalidomide—leprosy	0.019	0.0196	CcSEcCtD
Methyldopa—Gynaecomastia—Thalidomide—leprosy	0.0177	0.0182	CcSEcCtD
Methyldopa—Lightheadedness—Thalidomide—leprosy	0.0177	0.0182	CcSEcCtD
Methyldopa—Eczema—Thalidomide—leprosy	0.016	0.0165	CcSEcCtD
Methyldopa—Cardiac failure congestive—Thalidomide—leprosy	0.0158	0.0163	CcSEcCtD
Methyldopa—Libido decreased—Thalidomide—leprosy	0.0155	0.016	CcSEcCtD
Methyldopa—Disturbance in sexual arousal—Thalidomide—leprosy	0.0143	0.0147	CcSEcCtD
Methyldopa—Psychotic disorder—Thalidomide—leprosy	0.014	0.0145	CcSEcCtD
Methyldopa—Liver function test abnormal—Thalidomide—leprosy	0.0133	0.0137	CcSEcCtD
Methyldopa—Orthostatic hypotension—Thalidomide—leprosy	0.0131	0.0135	CcSEcCtD
Methyldopa—Breast disorder—Thalidomide—leprosy	0.013	0.0134	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Thalidomide—leprosy	0.0129	0.0133	CcSEcCtD
Methyldopa—Abdominal distension—Thalidomide—leprosy	0.0125	0.0129	CcSEcCtD
Methyldopa—Eosinophilia—Thalidomide—leprosy	0.0123	0.0127	CcSEcCtD
Methyldopa—Pancreatitis—Thalidomide—leprosy	0.0122	0.0125	CcSEcCtD
Methyldopa—Angina pectoris—Thalidomide—leprosy	0.0121	0.0125	CcSEcCtD
Methyldopa—Pancytopenia—Thalidomide—leprosy	0.0118	0.0121	CcSEcCtD
Methyldopa—Erectile dysfunction—Thalidomide—leprosy	0.0114	0.0118	CcSEcCtD
Methyldopa—Weight increased—Thalidomide—leprosy	0.0113	0.0116	CcSEcCtD
Methyldopa—Infestation NOS—Thalidomide—leprosy	0.0111	0.0114	CcSEcCtD
Methyldopa—Infestation—Thalidomide—leprosy	0.0111	0.0114	CcSEcCtD
Methyldopa—Body temperature increased—Dapsone—leprosy	0.0109	0.0112	CcSEcCtD
Methyldopa—Agranulocytosis—Thalidomide—leprosy	0.0103	0.0106	CcSEcCtD
Methyldopa—Bradycardia—Thalidomide—leprosy	0.0101	0.0104	CcSEcCtD
Methyldopa—Hepatitis—Thalidomide—leprosy	0.00994	0.0102	CcSEcCtD
Methyldopa—Cardiac disorder—Thalidomide—leprosy	0.00923	0.0095	CcSEcCtD
Methyldopa—Angiopathy—Thalidomide—leprosy	0.00902	0.00929	CcSEcCtD
Methyldopa—Mediastinal disorder—Thalidomide—leprosy	0.00896	0.00923	CcSEcCtD
Methyldopa—Vomiting—Dapsone—leprosy	0.00877	0.00903	CcSEcCtD
Methyldopa—Mental disorder—Thalidomide—leprosy	0.00871	0.00897	CcSEcCtD
Methyldopa—Headache—Dapsone—leprosy	0.00864	0.0089	CcSEcCtD
Methyldopa—Flatulence—Thalidomide—leprosy	0.00853	0.00878	CcSEcCtD
Methyldopa—Nausea—Dapsone—leprosy	0.0082	0.00844	CcSEcCtD
Methyldopa—DDC—nerve—leprosy	0.00777	0.319	CbGeAlD
Methyldopa—Leukopenia—Thalidomide—leprosy	0.00775	0.00798	CcSEcCtD
Methyldopa—Myalgia—Thalidomide—leprosy	0.00737	0.00759	CcSEcCtD
Methyldopa—Arthralgia—Thalidomide—leprosy	0.00737	0.00759	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.00732	0.00753	CcSEcCtD
Methyldopa—Oedema—Thalidomide—leprosy	0.00706	0.00727	CcSEcCtD
Methyldopa—Infection—Thalidomide—leprosy	0.00702	0.00723	CcSEcCtD
Methyldopa—Nervous system disorder—Thalidomide—leprosy	0.00693	0.00713	CcSEcCtD
Methyldopa—Thrombocytopenia—Thalidomide—leprosy	0.00692	0.00712	CcSEcCtD
Methyldopa—Skin disorder—Thalidomide—leprosy	0.00686	0.00706	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Thalidomide—leprosy	0.00644	0.00663	CcSEcCtD
Methyldopa—Paraesthesia—Thalidomide—leprosy	0.00634	0.00653	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Thalidomide—leprosy	0.0061	0.00628	CcSEcCtD
Methyldopa—Constipation—Thalidomide—leprosy	0.00604	0.00622	CcSEcCtD
Methyldopa—Body temperature increased—Thalidomide—leprosy	0.00558	0.00575	CcSEcCtD
Methyldopa—Hypersensitivity—Thalidomide—leprosy	0.0052	0.00536	CcSEcCtD
Methyldopa—Asthenia—Thalidomide—leprosy	0.00507	0.00522	CcSEcCtD
Methyldopa—Diarrhoea—Thalidomide—leprosy	0.00483	0.00498	CcSEcCtD
Methyldopa—Dizziness—Thalidomide—leprosy	0.00467	0.00481	CcSEcCtD
Methyldopa—Epinephrine—TNF—leprosy	0.0045	1	CrCbGaD
Methyldopa—Vomiting—Thalidomide—leprosy	0.00449	0.00462	CcSEcCtD
Methyldopa—Rash—Thalidomide—leprosy	0.00445	0.00459	CcSEcCtD
Methyldopa—Dermatitis—Thalidomide—leprosy	0.00445	0.00458	CcSEcCtD
Methyldopa—Headache—Thalidomide—leprosy	0.00443	0.00456	CcSEcCtD
Methyldopa—Nausea—Thalidomide—leprosy	0.0042	0.00432	CcSEcCtD
Methyldopa—ADRA2A—peripheral nervous system—leprosy	0.00335	0.138	CbGeAlD
Methyldopa—COMT—eye—leprosy	0.00215	0.0882	CbGeAlD
Methyldopa—COMT—skin of body—leprosy	0.00187	0.0767	CbGeAlD
Methyldopa—DDC—testis—leprosy	0.00178	0.0732	CbGeAlD
Methyldopa—DDC—nervous system—leprosy	0.00175	0.0718	CbGeAlD
Methyldopa—COMT—tendon—leprosy	0.00142	0.0584	CbGeAlD
Methyldopa—COMT—testis—leprosy	0.00118	0.0484	CbGeAlD
Methyldopa—COMT—nervous system—leprosy	0.00116	0.0475	CbGeAlD
Methyldopa—ADRA2A—tendon—leprosy	0.000724	0.0298	CbGeAlD
Methyldopa—ADRA2A—testis—leprosy	0.000599	0.0246	CbGeAlD
Methyldopa—ADRA2A—nervous system—leprosy	0.000588	0.0242	CbGeAlD
